Lumos Pharma, Inc. (LUMO) Tops Q1 EPS by 68c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Lumos Pharma Reports First Quarter 2020 Results and Provides Update on Clinical and Corporate Activities
May 28, 2020 4:01 PM EDT- Lumos Pharma expects to initiate its Phase 2b LUM-201 trial in Pediatric Growth Hormone Deficiency (PGHD) prior to the end of 2020
- Additional non-dilutive funds expected from anticipated monetization of priority review voucher (PRV)
- Cash on hand expected to fund current operations through Phase 2b trial read-out
AUSTIN, Texas, May 28, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma,... More
